All In Biotech

Drug Trial Radar · NCT04377750

The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation

Last checked: Nov 19, 2026Latest source record: May 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

500

Planned (sponsor's estimate)

Start

Apr 8, 2020

Primary completion

Apr 29, 2020

Study completion May 8, 2021

Sponsor

Lead sponsor
Hadassah Medical OrganizationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sheba Medical Center; Wolfson Medical Center
First posted
May 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Title: The use of Tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. This is a study designed to assess the therapeutic value of intravenous tocilizumab administered as single 8mg/Kg dose in patients affected by SARS-CoV2 infection with a pulmonary manifestation causing hypoxia. Aim of the study is to test the hypothesis that anti-IL6 treatment can be effective in reducing the virus-induced cytokine storm, blocking deterioration of lung function or even promoting a rapid improvement of clinical conditions, preventing tracheal intubation and/or death. This drug will be administered to those patients entering the ICU with severe acute respiratory failure COVID-19 disease. The endpoints are death and duration of hospitalization. The patients will be assessed with surrogate markers determining the level of the cytokine storm.

Conditions

  • Covid19 Pneumonia

Interventions

  • TocilizumabDrug

    The placebo treatment arm will include 100 ml of normal saline administered along 60 min

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SurvivalTime frame: One-month

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Barzilai Medical Center

    Ashkelon, Israel · Recruiting

  • Wolfson Medical Center

    Holon, Israel · Recruiting

  • Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Hadassah Medical Orginisation

    Jerusalem, Please Select:, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.